Gholam R. Berenji

Nuclear Medicine

11301 Wilshire Blvd
Nuclear Medicine (115)
Los Angeles, CA 90073

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels.

Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels.

Journal: EJNMMI research

Published: March 25, 2026

Current Status of Clinical 177Lu-PSMA Radiopharmaceutical Therapies: Insights from a Survey of High-End Nuclear Medicine Theranostic Centers.

Current Status of Clinical 177Lu-PSMA Radiopharmaceutical Therapies: Insights from a Survey of High-End Nuclear Medicine Theranostic Centers.

Journal: Journal of nuclear medicine technology

Published: March 07, 2026

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases.

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases.

Journal: PloS one

Published: August 29, 2025

Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy.

Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy.

Journal: European urology oncology

Published: April 16, 2025

Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease.

Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease.

Journal: European urology oncology

Published: May 28, 2024

Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.

Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.

Journal: European urology

Published: February 03, 2024

Better Late than Never for Late Toxicity Assessment.

Better Late than Never for Late Toxicity Assessment.

Journal: European urology

Published: January 26, 2023

Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement.

Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement.

Journal: European journal of hybrid imaging

Published: January 09, 2023

Comparison of Low-Energy and Medium-Energy Collimators for Thyroid Scintigraphy with 123I.

Comparison of Low-Energy and Medium-Energy Collimators for Thyroid Scintigraphy with 123I.

Journal: Journal of nuclear medicine technology

Published: May 04, 2021

Information Transfer and Multifractal Analysis of EEG in Mild Blast-Induced TBI.

Information Transfer and Multifractal Analysis of EEG in Mild Blast-Induced TBI.

Journal: Computational and mathematical methods in medicine

Published: October 09, 2020

Examining posttraumatic stress disorder as a key postinjury risk factor in OIF/OEF veterans with blast-induced mild traumatic brain injury.

Examining posttraumatic stress disorder as a key postinjury risk factor in OIF/OEF veterans with blast-induced mild traumatic brain injury.

Journal: Neuropsychology

Published: July 03, 2020

Focal 18F-NaF PET Prostate Activity in the Setting of Prostate Adenocarcinoma.

Focal 18F-NaF PET Prostate Activity in the Setting of Prostate Adenocarcinoma.

Journal: Clinical nuclear medicine

Published: May 15, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026